Skiplink Navigation

Main Features

Roche wins EU approval for cancer drug

Roche's research centre in Basel

(Keystone Archive)

The Swiss pharmaceutical giant, Roche, has been given the green light by the European Commission for its Xeloda drug - the first oral treatment for metastatic colorectal cancer.

In a statement, the Basel-based pharmaceutical group said Xeloda would be more effective than current treatments and easier for patients to take than intravenous chemotherapy.

The EU's backing follows two controlled tests involving 1200 patients. The drug is already approved for this use in many countries including Switzerland, Canada and Australia.

It's also used in the fight against breast cancer in more than 50 countries.

swissinfo with agencies


Neuer Inhalt

Horizontal Line

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletter and get the top stories delivered to your inbox.

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!